Autres langues Eterna Therapeutics Inc.

Actions

ERNA

US1140822099

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 07/06/2024			Varia. 5j.	Varia. 1 janv.
1,93 ^USD	-5,39 %		+1,58 %	+7,52 %

14/05	Eterna Therapeutics Inc. présente ses résultats pour le premier trimestre terminé le 31 mars 2024	CI
08/05	Eterna Therapeutics Inc. nomme Mahendra Rao à son conseil consultatif scientifique	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Eterna Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board	08/05
Eterna Therapeutics Inc. Appoints Mahendra Rao to Its Scientific Advisory Board	08/05
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M Locus	07/05
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases	07/05
Eterna Therapeutics Inc. to Present at the ASGCT 27Th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line	07/05
North American Morning Briefing : Inflation -2-	15/03
Eterna Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors	20/02
Eterna Therapeutics Inc. Announces Appointment of Peter Cicala, JD to Its Board of Directors	20/02
Eterna Therapeutics Inc. Announces Appointment of Peter Cicala to the Board of the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee	16/02
Eterna Therapeutics Inc. Announces Management Changes	19/01
Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)	03/01
Eterna Therapeutics Inc Announces Chief Executive Officer Changes, Effective January 1, 2024	21/12
Eterna Therapeutics Inc Appoints Sanjeev Luther as President and Member of the Board of Directors, Effective January 1, 2024	21/12
Eterna Therapeutics Inc. Appoints James Bristol as Chairman of the Board	20/12
Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer	20/12
Eterna Therapeutics Selling $9.2 Million of Convertible Promissory Notes, Accompanying Warrants	15/12
Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing	15/12
Eterna Therapeutics Inc. announced that it expects to receive $9.2 million in funding	14/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Eterna Therapeutics Inc.

Actions

ERNA

US1140822099

Autres langues

Filtres